Biogen (BIIB) Accounts Payables (2009 - 2026)

Biogen (BIIB) has reported Accounts Payables for 18 consecutive years, with $358.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables fell 8.43% year-over-year to $358.5 million; the TTM figure through Mar 2026 stood at $358.5 million (down 8.43% YoY), while the FY2025 annual figure was $432.0 million, up 1.84% from the prior year.
• Accounts Payables came in at $358.5 million for Q1 2026 at Biogen, down from $432.0 million in the prior quarter.
• The five-year high for Accounts Payables was $491.5 million in Q4 2022, with the low at $354.5 million in Q2 2024.
• Average Accounts Payables over 5 years is $416.5 million, with a median of $413.1 million recorded in 2025.
• Across the five-year window, Accounts Payables increased 23.2% in 2023 and retreated 21.21% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $491.5 million in 2022, then fell by 17.95% to $403.3 million in 2023, then grew by 5.18% to $424.2 million in 2024, then gained by 1.84% to $432.0 million in 2025, then dropped by 17.01% to $358.5 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $358.5 million, $432.0 million, and $413.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.